Compare Illinois Tool Works Inc. (ITW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs TG Therapeutics Inc — how do they compare? Illinois Tool Works Inc. trades at $273.3 (market cap $78.17B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Illinois Tool Works Inc. is far larger — about 9.5× TG Therapeutics Inc's market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ITW | TGTX | |
|---|---|---|
Market Cap | $78.17B | $8.26B |
Sector | Industrials | Health |
52-Week High | $299.60 | $59.06 |
52-Week Low | $241.07 | $26.39 |
Enterprise Value | $86.49B | $8.50B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $271.58, down 1.62% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 19.32% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights mixed sentiment, with some analysts citing premium valuation concerns while others note growth prospects from enterprise initiatives and a potential bullish chart pattern.
Outlook remains cautiously optimistic with a consensus price target of $288.25 offering ~6% upside. Key risks include valuation sensitivity, organic sales pressure in some segments, and macroeconomic headwinds. The upcoming Q2 2026 earnings report on July 28, 2026, will be critical for validating growth trajectory amid analyst divergence.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
